Thrivent Financial For Lutherans increased its holdings in shares of Globus Medical, Inc. (NYSE:GMED) by 7.9% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 14,560 shares of the medical device company’s stock after purchasing an additional 1,070 shares during the period. Thrivent Financial For Lutherans’ holdings in Globus Medical were worth $483,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in shares of Globus Medical by 0.3% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 10,538 shares of the medical device company’s stock worth $349,000 after purchasing an additional 31 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Globus Medical by 1.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 3,036 shares of the medical device company’s stock worth $100,000 after purchasing an additional 35 shares during the last quarter. Alps Advisors Inc. lifted its position in shares of Globus Medical by 0.3% during the 2nd quarter. Alps Advisors Inc. now owns 17,464 shares of the medical device company’s stock worth $579,000 after purchasing an additional 45 shares during the last quarter. Advantus Capital Management Inc lifted its position in shares of Globus Medical by 3.0% during the 1st quarter. Advantus Capital Management Inc now owns 9,209 shares of the medical device company’s stock worth $273,000 after purchasing an additional 270 shares during the last quarter. Finally, Renaissance Group LLC lifted its position in shares of Globus Medical by 2.4% during the 2nd quarter. Renaissance Group LLC now owns 11,591 shares of the medical device company’s stock worth $384,000 after purchasing an additional 277 shares during the last quarter. 65.40% of the stock is owned by institutional investors and hedge funds.

In other Globus Medical news, insider A Brett Murphy sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $29.99, for a total transaction of $449,850.00. Following the completion of the sale, the insider now directly owns 101,217 shares in the company, valued at $3,035,497.83. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 28.21% of the company’s stock.

GMED has been the subject of several research analyst reports. BidaskClub cut Globus Medical from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 26th. Zacks Investment Research cut Globus Medical from a “hold” rating to a “sell” rating in a research report on Monday, September 4th. Canaccord Genuity reissued a “buy” rating and set a $37.00 price objective on shares of Globus Medical in a research report on Friday, August 18th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Globus Medical in a research report on Wednesday, August 30th. Finally, BTIG Research initiated coverage on Globus Medical in a research report on Thursday, September 7th. They set a “buy” rating and a $37.00 price objective for the company. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $30.71.

Globus Medical, Inc. (GMED) opened at 29.40 on Wednesday. Globus Medical, Inc. has a 52 week low of $19.25 and a 52 week high of $34.03. The company’s 50-day moving average price is $29.91 and its 200 day moving average price is $30.89. The company has a market capitalization of $2.83 billion, a price-to-earnings ratio of 26.49 and a beta of 0.56.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Wednesday, August 2nd. The medical device company reported $0.32 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.30 by $0.02. The firm had revenue of $152.39 million during the quarter, compared to the consensus estimate of $150.94 million. Globus Medical had a net margin of 18.12% and a return on equity of 13.99%. The business’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same period last year, the business posted $0.29 earnings per share. On average, analysts predict that Globus Medical, Inc. will post $1.27 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/10/18/globus-medical-inc-gmed-shares-bought-by-thrivent-financial-for-lutherans.html.

About Globus Medical

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical, Inc. (NYSE:GMED).

Institutional Ownership by Quarter for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.